GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4Results posted

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance

Lead sponsor

The University of Texas Health Science Center at San Antonio

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes

Key I/E criteria

•BMI ≥27•Age 65-90

Primary endpoint

•Lean mass

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05786521

Org study ID20220256HU

Secondary ID5P30AG044271-08

Timeline

Milestones

Study first posted2023-03-27actual

Study start2023-04-01actual

Primary completion2024-05-20actual

Study completion2024-05-20actual

Last update posted2025-05-04actual

Results first posted2025-05-04actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightPrediabetes / glucose intoleranceType 2 diabetes

Eligibility

Who can enroll

Minimum age65 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Older than 65

•Have prediabetes or diabetes

•BMI ≥ 27.0 kg/m2

•Living independently (not in assisted living or nursing home)

Exclusion criteria

•Have heart disease

•Have liver disease

•Smoke

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints

Primary/registry result

Lean Body Mass Change

Time frame:Baseline to 20 weeks

Lean mass

change from baseline, improvement

Posted result

Group	Value (mean), g	95% CI
Semaglutide and Lifestyle Intervention	-1730.6	-3063 – -398
Lifestyle Intervention	-421	-1745 – 911

Primary/protocol endpoint

Lean Body Mass Change

Time frame:Baseline to 20 weeks

Lean mass

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis.
Frontiers in aging2025 (year)PMID41393101doi:10.3389/fragi.2025.1691007via pubmed nct search
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
JMIR research protocols2024 Sep 13PMID39269759doi:10.2196/62667via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.